Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis

Canadian Journal of Cardiology

Volumn 19, Issue 2, 2003, Pages 161-166

  Brown, Ruth ^a   Armstrong, Paul W ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute angina; Cost effectiveness, Canada; Eptifibatide; Non Q wave myocardial infarction; Non ST segment acute coronary syndromes

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; REO PRO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIAGNOSTIC TEST; DRUG CHOICE; DRUG COST; DRUG EFFECT; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MODEL; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESOURCE MANAGEMENT; ST SEGMENT ELEVATION; STANDARD; SURVIVAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MODELS, ECONOMIC; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; UTILIZATION REVIEW;

EID: 0037356965     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
2. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
3. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-35.
4. Goa KL, Noble S. Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999;57:439-62.
5. Mark DB, Harrington RA, Lincoff AM, et al. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-71.
6. Fu Y, Chang W-C, Mark D, et al. Canadian-American differences in the management of acute coronary syndromes in GUSTO IIb: One year follow-up of patients with versus those without ST segment elevation. Circulation 2000;102:1375-81.
7. McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 1997;80:B39-43.
8. Hillegass WB, Newman AR, Raco DL. Economic issues in glycoprotein IIb/IIIa receptor therapy. Am Heart J 1999;138:S24-32.
9. Henderson RA, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: An economic substudy of the PURSUIT trial. Eur Heart J 1999;1(Suppl N):N35-41.
10. Ontario Case Cost Project (OCCP). Ontario guide to case costing. Report #1.1. Ottawa: Ontario Ministry of Health, 1995. Available at: Version current at January 27, 2003.
11. Ontario Ministry of Health. Schedule of Benefits: Physician Services Under the Health Insurance Act. Ottawa: Ontario Ministry of Health, 1992.
12. Ministry of Health, Emergency Health Services Branch. Ambulance Co-Payment Billing Manual. Ottawa: Ontario Ministry of Health, 1992.
13. Canadian Co-ordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd edn. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
14. Zed PJ, Frighetto L, Sunderji R, Marra CA. Cost-effectiveness analysis of abciximab: A Canadian hospital perspective. Ann Pharmacother 1998;32:S36-42.
15. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
16. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with the tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
17. Statistics Canada. Vital Statistics. Section 2. Expectation of life and expected death, by race, sex, and age: 1992. 1995;116-87. Version current at January 16, 2003.
18. Statistics Canada. Life Tables, Canada and Provinces 1990-1992. Table 2. 1995;84-537. p.96. Version current at January 16, 2003.
19. Harrington RA, Lincoff AM, Berdan LG, et al. Maintenance of clinical benefit at six-months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. Circulation 1998;(Suppl 1):359. (Abst no 1886)